NewLimit raised $45 million in a financing round that included Lilly Ventures and S32, the company said. The funding will support clinical development of NewLimit’s programs targeting age‑related biology and metabolic drivers of aging. Investors framed the round as validation of a growing commercial interest in translational geroscience. The capital will advance Phase 1/2 programs and biomarker development as NewLimit positions itself among a crop of startups seeking to commercialize longevity interventions.